Advancement in our understanding of GLP-1 signaling and its role in glucose metabolism has led to the development of several pharmacologically active GLP-1 receptor agonists, such as liraglutide, exenatide, and semaglutide, for the treatment of type 2 diabetes [14,15,29]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.